Attached files
| file | filename |
|---|---|
| EX-31.1 - EXHIBIT 31.1 - Outlook Therapeutics, Inc. | tm1919825d1_ex31-1.htm |
| EX-23.1 - EXHIBIT 23.1 - Outlook Therapeutics, Inc. | tm1919825d1_ex23-1.htm |
| EX-10.13 - EXHIBIT 10.13 - Outlook Therapeutics, Inc. | tm1919825d1_ex10-13.htm |
| 10-K - FORM 10-K - Outlook Therapeutics, Inc. | tm1919825d1_10k.htm |
Exhibit 32.1
CERTIFICATION PURSUANT
TO18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Outlook Therapeutics, Inc. (the “Registrant”) certifies that the Annual Report of Outlook Therapeutics, Inc. on Form 10-K for the year ended September 30, 2019 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, and that information contained in the Report fairly presents in all material respects the financial condition and results of operations of the Registrant.
| Date: December 19, 2019 | By: | /s/ Lawrence A. Kenyon |
| Name: | Lawrence A. Kenyon | |
| Title: | Chief Executive Officer and Chief Financial Officer | |
| (Principal Executive, Financial and Accounting Officer) |
A signed original of this written statement required by Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350 has been provided to the Registrant and will be retained by the Registrant and furnished to the Securities and Exchange Commission or its staff upon request.
This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.